A bispecific in biliary tract cancer, dostarlimab organ preservation in rectal cancer, and KRAS G12D data in pancreatic cancer stood out at ESMO 2026.
News|Articles|June 17, 2026
From Conference to Practice: Top 5 Takeaways From EHA 2026
Author(s)Russ Conroy
Fact checked by: Ariana Pelosci, Justin Mancini
This year’s EHA Congress saw potential advances across multiple myeloma, leukemia, lymphoma, and other hematologic malignancy populations.
Advertisement
Advertisement
The future of hematologic oncology was recently unveiled in Stockholm, Sweden.
Related to this article
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Catch up on 5 melanoma and skin cancer readouts from ESMO 2026, including NADINA, OptimUM-01, OptimUM-09, C-POST, and KEYNOTE-630.
ESMO 2026 posters showed durable EV-302 benefit in older and comorbid populations plus persistent early mortality in metastatic urothelial carcinoma.
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.
Adam C. Olson, MD, MSc-GH, discussed the infrastructure, training, and shared decision-making behind building a prostate HDR brachytherapy program.
Advertisement
Advertisement